PROVIDENCE, R.I.--(BUSINESS WIRE)--A novel therapy under development by Tivorsan Pharmaceuticals demonstrated reduction of muscle pathology and improved muscle function in a mouse model of Duchenne Muscular Dystrophy (DMD). The company is actively working towards human clinical studies with a proprietary form of the natural biglycan protein, which appears to have a unique mechanism of action that may apply to all genetic forms of DMD.
